Igene Biotechnology Financials
We strongly advise to harness Igene Biotechnology fundamental analysis to find out if markets are presently mispricing the company. Simply put you can make use of it to find out if Igene Biotechnology is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to interpolate twenty-eight available reported financial drivers for Igene Biotechnology, which can be compared to its competitors.
Igene |
Understanding current and past Igene Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Igene Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in Igene Biotechnology's assets may result in an increase in income on the income statement.
Please note, the presentation of Igene Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Igene Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Igene Biotechnology's management manipulating its earnings.
Igene Biotechnology Stock Summary
Igene Biotechnology competes with KS AG, Intrepid Potash, and Bioceres Crop. Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE BIOTECHNOLOGY operates under Agricultural Inputs classification in the United States and is traded on PNK Exchange. It employs 18 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US4516951005 |
| Business Address | 9110 Red Branch |
| Sector | Chemicals |
| Industry | Materials |
| Benchmark | Dow Jones Industrial |
| Website | www.igene.com |
| Phone | 410 997 2599 |
| Currency | USD - US Dollar |
Igene Biotechnology Key Financial Ratios
There are many critical financial ratios that Igene Biotechnology's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Igene Biotechnology reports annually and quarterly.| Return On Asset | -0.0821 | |||
| Number Of Employees | 18 | |||
| Beta | -2.8 | |||
| Z Score | -15.4 |
Igene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Igene Biotechnology's current stock value. Our valuation model uses many indicators to compare Igene Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Igene Biotechnology competition to find correlations between indicators driving Igene Biotechnology's intrinsic value. More Info.Igene Biotechnology is rated third overall in return on asset category among its peers. It is rated fourth overall in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Igene Biotechnology's earnings, one of the primary drivers of an investment's value.Igene Biotechnology Systematic Risk
Igene Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Igene Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Igene Biotechnology correlated with the market. If Beta is less than 0 Igene Biotechnology generally moves in the opposite direction as compared to the market. If Igene Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Igene Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Igene Biotechnology is generally in the same direction as the market. If Beta > 1 Igene Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Complementary Tools for Igene Pink Sheet analysis
When running Igene Biotechnology's price analysis, check to measure Igene Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Igene Biotechnology is operating at the current time. Most of Igene Biotechnology's value examination focuses on studying past and present price action to predict the probability of Igene Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Igene Biotechnology's price. Additionally, you may evaluate how the addition of Igene Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |